MX337436B - Proteina de funsion anticancer. - Google Patents

Proteina de funsion anticancer.

Info

Publication number
MX337436B
MX337436B MX2013006213A MX2013006213A MX337436B MX 337436 B MX337436 B MX 337436B MX 2013006213 A MX2013006213 A MX 2013006213A MX 2013006213 A MX2013006213 A MX 2013006213A MX 337436 B MX337436 B MX 337436B
Authority
MX
Mexico
Prior art keywords
fusion protein
domain
sequence
terminus
anticancer fusion
Prior art date
Application number
MX2013006213A
Other languages
English (en)
Other versions
MX2013006213A (es
Inventor
Jerzy Szczepan Pieczykolan
Krysztof Kazimierz Lemke
Sebastian Pawlak
Bartlomiej Zerek
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL393146A external-priority patent/PL393146A1/pl
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of MX2013006213A publication Critical patent/MX2013006213A/es
Publication of MX337436B publication Critical patent/MX337436B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una proteína de fusión que comprende un dominio (a) que es un fragmento funcional de la secuencia de proteína hTRAIL, cuyo fragmento empieza con un aminoácido en una posición no menor que hTRAIL95, o un homólogo de dicho fragmento funcional que tiene por lo menos 70% de identidad de secuencia; y un dominio (b) que es una secuencia de un péptido efector inmunoestimulante, en donde la secuencia del dominio (b) está unida en el C-terminal o el N-terminal del dominio (a); la proteína de fusión puede ser utilizada para el tratamiento de enfermedades de cáncer.
MX2013006213A 2010-12-03 2011-12-05 Proteina de funsion anticancer. MX337436B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL393146A PL393146A1 (pl) 2010-12-03 2010-12-03 Przeciwnowotworowe białko fuzyjne
PL39459711 2011-04-18
PCT/EP2011/071719 WO2012072815A1 (en) 2010-12-03 2011-12-05 Anticancer fusion protein

Publications (2)

Publication Number Publication Date
MX2013006213A MX2013006213A (es) 2013-07-29
MX337436B true MX337436B (es) 2016-03-03

Family

ID=45065918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006213A MX337436B (es) 2010-12-03 2011-12-05 Proteina de funsion anticancer.

Country Status (27)

Country Link
US (1) US9161991B2 (es)
EP (1) EP2646464B1 (es)
JP (1) JP5759557B2 (es)
KR (1) KR101952460B1 (es)
CN (1) CN103237808B (es)
AU (1) AU2011334868B2 (es)
BR (1) BR112013013548B8 (es)
CA (1) CA2814595C (es)
CY (1) CY1116646T1 (es)
DK (1) DK2646464T3 (es)
EA (1) EA024452B1 (es)
ES (1) ES2545895T3 (es)
HK (1) HK1186192A1 (es)
HR (1) HRP20150664T1 (es)
HU (1) HUE027068T2 (es)
IL (1) IL226207A (es)
ME (1) ME02224B (es)
MX (1) MX337436B (es)
NZ (1) NZ609216A (es)
PL (1) PL2646464T3 (es)
PT (1) PT2646464E (es)
RS (1) RS54057B1 (es)
SG (2) SG10201509676UA (es)
SI (1) SI2646464T1 (es)
SM (1) SMT201500203B (es)
WO (1) WO2012072815A1 (es)
ZA (1) ZA201303449B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
US11136353B2 (en) 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
BR112022020440A2 (pt) 2020-04-10 2022-12-27 Cytomx Therapeutics Inc Construtos de citocinas ativáveis e composições e métodos relacionados
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
KR20230169700A (ko) 2022-06-09 2023-12-18 제주대학교 산학협력단 Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240068191A (ko) 2022-11-10 2024-05-17 제주대학교 산학협력단 리모닌을 유효성분으로 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240072614A (ko) 2022-11-17 2024-05-24 제주대학교 산학협력단 감귤 무봉 추출물을 유효성분으로 포함하는 탈모증상의 예방 개선 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
CA2411967A1 (en) * 2000-06-09 2001-12-20 The Government Of The United States Of America, As Represented By The Se Cretary Of The Departent Of Health And Human Services Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
DE60141992D1 (es) * 2000-09-05 2010-06-10 Biosight Ltd
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
US7666989B2 (en) 2003-11-03 2010-02-23 Beijing Sunbio Biotech Co., Ltd. Recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
ZA200800974B (en) 2005-08-16 2009-11-25 Genentech Inc Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
EP3072903B1 (en) * 2007-07-10 2017-10-25 Apogenix AG Tnf superfamily collectin fusion proteins
CA3128656A1 (en) * 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
TW200950778A (en) 2008-05-14 2009-12-16 Genentech Inc Methods of using Apo2L/TRAIL to treat cancer
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme

Also Published As

Publication number Publication date
CN103237808A (zh) 2013-08-07
US20130251676A1 (en) 2013-09-26
ZA201303449B (en) 2014-01-29
BR112013013548A2 (pt) 2016-10-11
IL226207A (en) 2016-07-31
HUE027068T2 (en) 2016-08-29
SI2646464T1 (sl) 2015-07-31
PL2646464T3 (pl) 2015-10-30
AU2011334868B2 (en) 2015-01-22
EP2646464B1 (en) 2015-06-03
WO2012072815A1 (en) 2012-06-07
IL226207A0 (en) 2013-07-31
CA2814595A1 (en) 2012-06-07
AU2011334868A1 (en) 2013-05-02
SG189370A1 (en) 2013-05-31
EA024452B1 (ru) 2016-09-30
CN103237808B (zh) 2016-02-24
HRP20150664T1 (hr) 2015-07-31
PT2646464E (pt) 2015-10-05
EP2646464A1 (en) 2013-10-09
CA2814595C (en) 2020-06-16
KR20130122764A (ko) 2013-11-08
NZ609216A (en) 2014-05-30
BR112013013548B1 (pt) 2022-03-29
SG10201509676UA (en) 2015-12-30
JP5759557B2 (ja) 2015-08-05
SMT201500203B (it) 2015-10-30
EA201390820A1 (ru) 2013-12-30
CY1116646T1 (el) 2017-03-15
DK2646464T3 (en) 2015-08-24
ES2545895T3 (es) 2015-09-16
KR101952460B1 (ko) 2019-02-27
HK1186192A1 (en) 2014-03-07
MX2013006213A (es) 2013-07-29
RS54057B1 (en) 2015-10-30
US9161991B2 (en) 2015-10-20
BR112013013548B8 (pt) 2022-11-08
JP2014502158A (ja) 2014-01-30
ME02224B (me) 2016-02-20

Similar Documents

Publication Publication Date Title
PH12014501083A1 (en) Anticancer fusion protein
MX337436B (es) Proteina de funsion anticancer.
MX339203B (es) Proteina de fusion anticancer.
MX2014008028A (es) Proteina de fusion anticancerigena.
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
EP3363458A3 (en) A peptide
RU2021134101A (ru) Модифицированная j-цепь
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2014057436A3 (en) Anticancer conjugate
WO2012143477A3 (en) Anticancer fusion protein
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
WO2019081595A3 (en) Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
GB0818080D0 (en) Immunogenic peptides
GB201019467D0 (en) Therapeutic agent
UA108911C2 (xx) Протираковий злитий протеїн
AR079370A1 (es) Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis
WO2015132103A3 (en) Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
TH139454A (th) การใช้แหล่ง l3และ/หรือ l5 ในฐานะเป็นวัคซีน หรือในเชิงวินิจฉัยสำหรับโรคปรสิต

Legal Events

Date Code Title Description
FG Grant or registration